Cargando…

Cholesterol efflux capacity assay using immobilized liposomes and apolipoprotein B-depleted serum

Cholesterol efflux capacity (CEC), an important functional step in reverse cholesterol transport, is the main anti-atherosclerotic function of high-density lipoprotein (HDL). Assays that improve the determination of CEC ex vivo for clinical applications are constantly explored. In the accompanying a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sapa, Hima Rani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2019
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579979/ https://www.ncbi.nlm.nih.gov/pubmed/31152112 http://dx.doi.org/10.1042/BSR20190619

Ejemplares similares

Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads
por: Horiuchi, Yuna, et al.
Publicado: (2019)

Validation and application of a novel cholesterol efflux assay using immobilized liposomes as a substitute for cultured cells
por: Horiuchi, Yuna, et al.
Publicado: (2018)

Comparison of a novel cholesterol efflux assay using immobilized liposome-bound gel beads with the conventional method
por: Horiuchi, Yuna, et al.
Publicado: (2020)

Development and validation of novel automatable assay for cholesterol efflux capacity
por: Mutsuda, Yume, et al.
Publicado: (2023)

Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes
por: Ballerini, Patrizia, et al.
Publicado: (2006)

Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages
por: Yao, Shuang, et al.
Publicado: (2021)

Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein
por: Schilcher, Irene, et al.
Publicado: (2017)

Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells
por: Yano, Kouji, et al.
Publicado: (2016)

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients
por: Zheng, Bo, et al.
Publicado: (2020)

A commentary on the paper, ‘Development and validation of a novel automatable assay for cholesterol efflux capacity’
por: Bhale, Aishwarya Sudam, et al.
Publicado: (2023)

Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure
por: Bigazzi, Federico, et al.
Publicado: (2017)

Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Yanagi, Yasuo, et al.
Publicado: (2022)

Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies
por: Hokstad, Ingrid, et al.
Publicado: (2022)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

Low HDL Cholesterol Efflux Capacity Indicates a Fatal Course of COVID-19
por: Stadler, Julia T., et al.
Publicado: (2022)

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma
por: Adorni, Maria Pia, et al.
Publicado: (2022)

Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects
por: Vuilleumier, Nicolas, et al.
Publicado: (2019)

Caveolin-1-Mediated Apolipoprotein A-I Membrane Binding Sites Are Not Required for Cholesterol Efflux
por: Le Lay, Soazig, et al.
Publicado: (2011)

Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
por: Choi, Seungbum, et al.
Publicado: (2013)

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2018)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
por: Kutkiene, Sandra, et al.
Publicado: (2019)

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux
por: Islam, Rafique M., et al.
Publicado: (2018)

Conformational flexibility of apolipoprotein A-I amino- and carboxy-termini is necessary for lipid binding but not cholesterol efflux
por: Bedi, Shimpi, et al.
Publicado: (2022)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: Contois, John H., et al.
Publicado: (2023)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Association of Cholesterol Efflux Capacity With Clinical Features of Metabolic Syndrome: Relevance to Atherosclerosis
por: Gall, Julie, et al.
Publicado: (2016)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy
por: Kockx, Maaike, et al.
Publicado: (2022)

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
Publicado: (2023)

Facile Cholesterol Loading with a New Probe ezFlux Allows for Streamlined Cholesterol Efflux Assays
por: Ravodina, Anastasia M., et al.
Publicado: (2020)

An assay to evaluate the capacity of cholesterol acceptors using BODIPY-cholesterol in cells
por: Raulin, Ana-Caroline, et al.
Publicado: (2023)

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
por: Zheng, Bo, et al.
Publicado: (2022)

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity
por: Rubinow, Katya B., et al.
Publicado: (2012)

In Vivo Inflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL
por: Franssen, Remco, et al.
Publicado: (2012)

Cholesterol Efflux Capacity and Cardiovascular Disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study
por: Ritsch, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hl552i59gfsv5aenke5kk6cfc5